At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
ridaforolimusdrug
Likely dose
ridaforolimus 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Pharmacokinetics of Ridaforolimus in Chinese Patients
In Brief
A Phase 1 clinical trial evaluating ridaforolimus for Cancer, Advanced. Completed, enrolled 15 participants.
Detailed Summary
Part 1 of the study will assess the pharmacokinetics, safety, and tolerability of ridaforolimus (MK-8669) after administration of single and multiple 40 mg doses in Chinese participants with advanced cancer. Part 2 of the study is optional; participants can continue to receive the study treatment in a weekly regimen of daily oral doses of ridaforolimus 40 mg for five consecutive days followed by two days off-treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Advanced
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartJul 2011
Primary CompletionOct 2011
Study CompletionApr 2012
TodayJul 2026
First PostedJun 27, 2011
Enrollment StartJul 5, 2011
Primary CompletionOct 20, 2011
Study CompletionApr 5, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.0 years ago
Interventions
ridaforolimusdrug
4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)